A National Collaborative Multicenter Phase II Study for Potential Safety Efficacy of Convalescent Plasma to Treat Severe COVID-19 Patients

MLA

Hind Alhumaidan, et al. “A National Collaborative Multicenter Phase II Study for Potential Safety Efficacy of Convalescent Plasma to Treat Severe COVID-19 Patients.” Blood, vol. 136, Aug. 2021, pp. 42–43. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....238c74df3673962498c8cd403b6dc5ec&authtype=sso&custid=ns315887.

APA

Hind Alhumaidan, Ghada Elgohary, Ahmed Al Bahrani, Abdul Rehman Z. Zaidi, Nour AlMozain, Hazzaa Alzahrani, Ahmed Alaskar, A. N. Abdulhamid, Syed Ziauddin A. Zaidi, Jawaher Mubarak Alotaibi, Osamah Khojah, Afra Dayel, Mona Alfaraj, Nawal AlShehry, Rehab Al-Ansari, H. Al Hashmi, D. Alawami, Mohammed Albalawi, R. Abdallah, … A. AlFraedhi. (2021). A National Collaborative Multicenter Phase II Study for Potential Safety Efficacy of Convalescent Plasma to Treat Severe COVID-19 Patients. Blood, 136, 42–43.

Chicago

Hind Alhumaidan, Ghada Elgohary, Ahmed Al Bahrani, Abdul Rehman Z. Zaidi, Nour AlMozain, Hazzaa Alzahrani, Ahmed Alaskar, et al. 2021. “A National Collaborative Multicenter Phase II Study for Potential Safety Efficacy of Convalescent Plasma to Treat Severe COVID-19 Patients.” Blood 136 (August): 42–43. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....238c74df3673962498c8cd403b6dc5ec&authtype=sso&custid=ns315887.